PACE-CME

Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD

Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
RestartResume
3' education - Nov. 7, 2022 - Prof. Pamela Douglas, MD
  • Overview

    AHA 2022 "We feel that a precision pathway -consisting of deferred testing by quantitative analysis and CCTA with selective FFR- is a preferred strategy in stable patients with suspected CAD", says Prof. Douglas.

  • Educational information

    This video was recorded during the American Heart Association’s Scientific Sessions 2022 in Chicago, IL, USA.

  • Faculty

    Pamela S Douglas MD is the Ursula Geller Professor of Research in Cardiovascular Diseases in the Department of Medicine at Duke University and Director of the Multimodality Imaging Program at Duke Clinical Research Institute, Durham, NC, USA.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of the PRECISE trial

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free